As previously announced, Mendus AB (publ) (“Mendus”) has, through a board resolution with subsequent approval by the extraordinary general meeting on December 16, 2025, issued 1,641,207 ordinary shares in a directed share issue.

As a result thereof, the number of shares and votes in Mendus has changed. The issues of shares have resulted in an increase in the number of ordinary shares from 60,943,371 ordinary shares to 62,584,578 ordinary shares.

As of December 30, 2025, the last trading day of the month, there was a total of 62,584,578 ordinary shares and votes in Mendus.

For more information, please contact:
Erik Manting
Chief Executive Officer
E-mail: ir@mendus.com

About Mendus AB (publ)
Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving long-term survival for cancer patients, while preserving health and quality of life. We leverage our understanding of dendritic cell biology to develop an advanced clinical pipeline of immunotherapies that combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. https://www.mendus.com/

This information is information that Mendus AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2025-12-30 08:00 CET.

Attachments
Change in number of shares and votes in Mendus AB (publ)

Läs mer på MFN